<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629962</url>
  </required_header>
  <id_info>
    <org_study_id>AT-03A-017</org_study_id>
    <nct_id>NCT05629962</nct_id>
  </id_info>
  <brief_title>SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in&#xD;
      adults with COVID-19 who do not need to be in the hospital but who are at high risk for&#xD;
      progression to severe disease. Eligible subjects will be randomly assigned (by chance) to&#xD;
      receive BEM or matching placebo orally for 5 days. Co-administration of locally available&#xD;
      standard of care (SOC) is allowed. The total duration of the study is 60 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects hospitalized for any cause or died due to any cause</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects hospitalized due to COVID-19 or died due to any cause</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who died due to any cause</measure>
    <time_frame>Day 1 through Day 29; Day 1 through Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with COVID-19-related complications</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with COVID-19-medically attended visits (hospitalization, emergency room (ER) visit, urgent care visit, physician's office visit, or telemedicine visit) or who died due to any cause</measure>
    <time_frame>Day 1 through Day 29; Day 1 through Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with COVID-19 symptom relapse</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with viral load rebound</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>SARS CoV 2 Infection</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Bemnifosbuvir (BEM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemnifosbuvir (BEM)</intervention_name>
    <description>BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days</description>
    <arm_group_label>Bemnifosbuvir (BEM)</arm_group_label>
    <other_name>AT-527</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive SARS-CoV-2 test conducted ≤ 5 days prior to randomization&#xD;
&#xD;
          -  Mild or moderate COVID-19 with symptom onset ≤ 5 days before randomization and at&#xD;
             least one COVID-19 related symptom present at time of screening&#xD;
&#xD;
          -  Subject must be high risk, defined below:&#xD;
&#xD;
               1. Age ≥80 years OR&#xD;
&#xD;
               2. Age ≥65 years with one of the following: i) obesity (body mass index [BMI] ≥30&#xD;
                  kg/m2) ii) diabetes mellitus iii) cardiovascular disease or hypertension iv)&#xD;
                  chronic lung disease requiring routine therapy OR&#xD;
&#xD;
               3. Age ≥18 years with one of the following: i) Down syndrome, sickle cell disease,&#xD;
                  dementia, Parkinson's disease, or care home residents ii) One of the following&#xD;
                  immunocompromising conditions or immunosuppressive treatment: receiving&#xD;
                  chemotherapy or other therapies for cancer, hematologic malignancy, being within&#xD;
                  2 years from receiving a hematopoietic stem cell or at any time following a solid&#xD;
                  organ transplant, human immunodeficiency virus (HIV) infection untreated or with&#xD;
                  CD4+ T lymphocyte count &lt;350 cells per cubic millimeter within the past 6 months,&#xD;
                  combined primary immunodeficiency disorder, taking immunosuppressive medications&#xD;
&#xD;
          -  Use of adequate contraception for females of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe or critical COVID-19 illness&#xD;
&#xD;
          -  Admitted to a hospital within 90 days prior to randomization due to COVID-19&#xD;
&#xD;
          -  Use of other investigational drugs within 30 days prior to planned dosing, or plans to&#xD;
             enroll in another clinical trial of an investigational agent while participating in&#xD;
             the present study&#xD;
&#xD;
          -  Initiation or planned initiation of remdesivir for treatment of the current SARS-CoV-2&#xD;
             infection&#xD;
&#xD;
          -  Requirement of prohibited medications, including hydroxychloroquine or amiodarone&#xD;
             within 3 months prior to screening. Note: Subjects who had already initiated any&#xD;
             COVID-19 drug with antiviral effects intended to treat symptomatic SARS-CoV-2&#xD;
             infection (≥ 24 hours prior to randomization) will be excluded. During screening (or&#xD;
             within 24 hours prior to or after randomization), locally available COVID-19 drugs&#xD;
             with antiviral effects (including but not limited to Paxlovid, molnupiravir,&#xD;
             favipiravir, monoclonal antibodies) will be permitted, as long as there are no&#xD;
             concerns for drug interactions.&#xD;
&#xD;
          -  Other known active viral or bacterial infection at the time of screening, such as&#xD;
             influenza and respiratory syncytial virus (RSV). Note: This exclusion does not apply&#xD;
             to subjects with stable chronic viral infections, such as chronic hepatitis C virus&#xD;
             (HCV) or HIV providing other eligibility criteria are met.&#xD;
&#xD;
          -  Receiving dialysis or have known moderate to severe renal impairment&#xD;
&#xD;
          -  History of severe hepatic impairment (Child-Pugh Class C)&#xD;
&#xD;
          -  Known allergy or hypersensitivity to components of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>1-(857) 284-8891</phone>
    <email>ateaclinicaltrials@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33179</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Splendora</city>
        <state>Texas</state>
        <zip>77372</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>70710-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Cachoeiro De Itapemirim</city>
        <state>Espirito Santo</state>
        <zip>2938-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Cuiabá</city>
        <state>Mato Grosso</state>
        <zip>78048</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59025</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <zip>89020-430</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Florianópolis</city>
        <state>Santa Catarina</state>
        <zip>88015</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <zip>88301</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <zip>89201</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13075</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01509</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Valinhos</city>
        <state>São Paulo</state>
        <zip>13271-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Nishi-ku</city>
        <state>Fukuoka City</state>
        <zip>819-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Fukuoka-Shi</city>
        <state>Fukuoka-Ken</state>
        <zip>810-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Timişoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Centelles</city>
        <state>Barcelona</state>
        <zip>8540</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Ankara</city>
        <zip>6230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Ankara</city>
        <zip>6800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 26, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>May 3, 2023</last_update_submitted>
  <last_update_submitted_qc>May 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

